Clinical trials: Osimertinib
Lung Adenocarcinoma
Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
This is an open label, phase II study to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR…
- Trial name
- NCT05528458
- Testing
- Osimertinib 80Mg Tab
- Where
- South Korea
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Healthy Volunteers
To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.
To determine the relative bioavailability of different oral formulations of AZD9291 and the effect of food in healthy volunteers.
- Trial name
- NCT01951599
- Testing
- AZD9291
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Oncology
A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291
The Sponsor is developing the study drug, AZD9291, for the potential treatment of nonsmall cell lung cancer. Lung cancer has been the most common cancer in the world for several decades and represents 12.8% of all new cancer…
- Trial name
- NCT02491944
- Testing
- AZD9291, [14C]AZD9291
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in Volunteers
Study to evaluate the pharmacokinetic and Mass Balance of single dose [14C] AZD9291 in healthy male volunteers
- Trial name
- NCT02096679
- Testing
- AZD9291
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer
There is no muture method to treat EGFR 20 insertion mutation non-small-cell lung cancer (NSCLC). the he purpose of this study is to study osimertinib combined with bevacizumab in the management of it.
- Trial name
- NCT04974879
- Testing
- Osimertinib Oral Tablet
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Qingdao Central Hospital
Healthy Volunteer
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
This is a Phase 1, open-label, 2-period fixed sequence design to evaluate the interaction of AZD9291 with omeprazole in approximately 50 healthy, adult male volunteers.
- Trial name
- NCT02224053
- Testing
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing
- Where
- 2 sites in United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers
To assess the pharmacokinetics of TY-9591 tablets and Osimertinib Mesylate tablets after a single fasting administration and the effect of food on the pharmacokinetics of TY-9591 tablets in healthy volunteers.
- Trial name
- NCT04798638
- Testing
- TY-9591 Tablets under Fasted Condition - Arm1, Osimertinib Mesylate Tablets under Fasted Condition - Arm1, TY-9591 Tablets after a High-fat Meal - Arm1
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- TYK Medicines, Inc